Apaziquone

Last updated
Apaziquone
Apaziquone.svg
Clinical data
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C15H16N2O4
Molar mass 288 g/mol g·mol−1
3D model (JSmol)
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Apaziquone (tentative trade name EOquin) [1] is an indolequinone that is a bioreductive prodrug similar to the older chemotherapeutic agent mitomycin C. In hypoxic cells, such as those on the inner surface of the urinary bladder, apaziquone is converted to active metabolites by intracellular reductases. The active metabolites alkylate DNA and lead to apoptosis. [2] This activity is preferentially expressed in neoplastic cells.

After administration of apaziquone directly into the urinary bladder (intravesically), the drug and its active metabolite were not detected in plasma, and there were no systemic side effects. [3] [4]

Apaziquone has been applied in clinical studies sponsored by Spectrum Pharmaceuticals and Allergan for the treatment of superficial (non-muscle invasive) bladder cancer. [3] Approximately 70% of all newly diagnosed patients with bladder cancer have non-muscle invasive bladder cancer and over one million patients in the United States and Europe are affected by the disease. The U.S. Food and Drug Administration (FDA) has granted Fast Track review status to apaziquone for this indication. [5]

Related Research Articles

Interstitial cystitis chronic inflammatory condition of the submucosal and muscular layers of the bladder

Interstitial cystitis (IC), also known as bladder pain syndrome (BPS), is a type of chronic pain that affects the bladder. Symptoms include feeling the need to urinate right away, needing to urinate often, and pain with sex. IC/BPS is associated with depression and lower quality of life. Many of those affected also have irritable bowel syndrome and fibromyalgia.

Benign prostatic hyperplasia noncancerous increase in size of the prostate

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.

Cystoscopy medical procedure; endoscopy of the urinary bladder via the urethra

Cystoscopy is endoscopy of the urinary bladder via the urethra. It is carried out with a cystoscope.

Bladder cancer urinary system cancer that results in malignant growth located in the urinary bladder

Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. It is a disease in which cells grow abnormally and have the potential to spread to other parts of the body. Symptoms include blood in the urine, pain with urination, and low back pain.

Prostatectomy Surgical removal of all or part of the prostate gland

Prostatectomy as a medical term refers to the surgical removal of all or part of the prostate gland. This operation is done for benign conditions that cause urinary retention, as well as for prostate cancer and for other cancers of the pelvis.

Tamsulosin chemical compound

Tamsulosin, sold under the trade name Flomax among others, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones. The evidence for benefit with a kidney stone is better when the stone is larger. It is taken by mouth.

Proteasome inhibitor drug that blocks the action of proteasomes, cellular complexes that break down proteins

Proteasome inhibitors are drugs that block the action of proteasomes, cellular complexes that break down proteins. They are being studied in the treatment of cancer; and three are approved for use in treating multiple myeloma.

Thiotepa is an alkylating agent used to treat cancer.

Transitional cell carcinoma carcinoma that derives from transitional epithelial cells

Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs in the urinary system. It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. It is the second most common type of kidney cancer, but accounts for only five to 10 percent of all primary renal malignant tumors.

Overactive bladder human disease

Overactive bladder (OAB) is a condition where there is a frequent feeling of needing to urinate to a degree that it negatively affects a person's life. The frequent need to urinate may occur during the day, at night, or both. If there is loss of bladder control then it is known as urge incontinence. More than 40% of people with overactive bladder have incontinence. Conversely, about 40% to 70% of urinary incontinence is due to overactive bladder. Overactive bladder is not life-threatening, but most people with the condition have problems for years.

Saw palmetto extract is an extract of the fruit of the saw palmetto. It is marketed as a treatment for benign prostatic hyperplasia (BPH), but reviews of clinical trials, including those conducted by the National Center for Complementary and Alternative Medicine, found it ineffective for this purpose.

UPK3A protein-coding gene in the species Homo sapiens

Uroplakin-3a is a protein that in humans is encoded by the UPK3A gene.

Chronic prostatitis/chronic pelvic pain syndrome

Chronic nonbacterial prostatitis, also known as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), is long term pelvic pain and symptoms with urination without evidence of a bacterial infection. It affects about 2 to 6% of men.

Oportuzumab monatox is an antineoplastic. Chemically, oportuzumab it is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule. The drug is produced by Viventia Bio, a Canadian company with laboratories in Winnipeg, Canada and headquarters in Philadelphia, Pennsylvania, USA. Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A.

NMP22 is a tumor marker for bladder cancer. NMP22 is the abbreviated form of Nuclear Matrix Protein Number 22. It reflects the mitotic activity of cells.

Urodynamic testing

Urodynamic testing or urodynamics is a study that assesses how the bladder and urethra are performing their job of storing and releasing urine. Urodynamic tests can help explain symptoms such as:

Mark S. Soloway, M.D. Mark Soloway is a leading authority in urologic cancer, researcher, former departmental Chair, medical professor and invitational lecturer. He served as Chairman of the University of Miami Miller School of Medicine Department of Urology and is currently a Professor at the Miller School of Medicine. Born in Cleveland, Dr. Soloway received his B.S. from Northwestern University in Chicago, Il (1961–1964) and completed his M.D. and residency at Case Western Reserve University School of Medicine in Cleveland, Ohio (1964–1970). He completed a fellowship at the National Cancer Institute of the National Institute of Health in Bethesda, MD (1970–1972). Dr. Soloway has received numerous awards for his work as a researcher and teacher, including the American Urological Association's Gold Cystoscope Award “For the individual who has contributed most to the field of urology within ten years of completion of his residency program” (1984), Mosby Scholarship for Scholastic Excellence (1967), North Central Section of American Urological Association Traveling Fellowship Award (1972) and many others.

Invasive urothelial carcinoma

Invasive urothelial carcinoma is a type of transitional cell carcinoma. It is a type of cancer that develops in the urinary system: the kidney, urinary bladder, and accessory organs. Transitional cell carcinoma is the most common type of bladder cancer and cancer of the ureter, urethra, renal pelvis, the ureters, the bladder, and parts of the urethra and urachus. It originates from tissue lining the inner surface of these hollow organs - transitional epithelium. The invading tumors can extend from the kidney collecting system to the bladder.

Surgery for benign prostatic hyperplasia Surgical procedure

If medical treatment is not effective, surgery may need to be performed for benign prostatic hyperplasia.

This is a timeline of bladder cancer, describing especially major discoveries and advances in treatment of the disease.

References

  1. ↑ "UvA researcher develops new bladder cancer medication". University of Amsterdam. 25 Jul 2007. Archived from the original on 2011-07-16.
  2. ↑ NCI. "apaziquone". Archived from the original on 9 May 2009. Retrieved 2009-06-07.
  3. 1 2 Puri R, Palit V, Loadman PM, et al. (October 2006). "Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer". J. Urol. 176 (4 Pt 1): 1344–8. arXiv: 1506.05421 . doi:10.1016/j.juro.2006.06.047. PMID   16952628.
  4. ↑ Hendricksen K, Gleason D, Young JM, et al. (July 2008). "Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer". J. Urol. 180 (1): 116–20. doi:10.1016/j.juro.2008.03.031. PMID   18485407.
  5. ↑ "FDA Designates Fast Track Status For Apaziquone (EOquin) For Bladder Cancer". Medical News Today. 22 Jul 2009.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.